We are proud to announce that our "Liver Cancer ctDNA Methylation Test" has been granted certification under the Laboratory Developed Tests (LDTs) program by the Taiwan Food and Drug Administration (TFDA).

This certification is a significant recognition of our years of dedication to research and validation. It also marks a crucial milestone on our path toward advancing the early detection and precision medicine for liver cancer.

The Liver Cancer ctDNA Methylation Test

The test works by analyzing the methylation status of circulating tumor DNA (ctDNA) found in the blood. This cutting-edge technology offers several key benefits:

• Earlier Screening: It helps fill the diagnostic gaps left by imaging or traditional biochemical tests, allowing more patients to receive treatment at an earlier stage.

• Reduced Need for Invasive Procedures: It provides patients with a lower-risk, repeatable monitoring tool, lessening the discomfort and risks associated with invasive examinations.

• Diagnostic Aid: It assists physicians in making more precise and accurate judgments about a patient's condition.

Liver cancer remains a major health threat in Taiwan. This certification confirms that our test can effectively help clinicians make earlier and more accurate decisions, ultimately benefiting a wide range of patients.